LABORATORY CORP OF AMERICA HOLDINGS

Form 8-K May 12, 2010

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

May 12, 2010
(Date of earliest event reported)

LABORATORY CORPORATION OF AMERICA HOLDINGS

(Exact Name of Registrant as Specified in its Charter)

DELAWARE	1-11353	13-3757370
(State or other jurisdiction of Incorporation)	(Commission File Number	•
358 SOUTH MAIN STREET, BURLINGTON, NORTH CAROLINA	27215	336-229-1127
(Address of principal executive offices)	(Zip Code)	(Registrant's telephone number including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 7.01. Regulation FD Disclosure

Summary information of the Company in connection with its Annual Meeting of Stockholders in Burlington, NC on May 12, 2010.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

<u>Laboratory Corporation of America Holdings</u> (Registrant)

Date: May 12, 2010 By: /s/F. Samuel Eberts III

F. Samuel Eberts III, Chief Legal Officer

and Secretary

May 12, 2010		
2010		
Annual Meeting		
of Stockholders		

2

This slide presentation contains forward-looking statements which are subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors.

Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect the Company s financial results is included in the Company s Form 10-K for the year ended December 31, 2009, and subsequent SEC filings.

Forward Looking Statement

Introduction

3

Leading National Lab Provider

Fastest growing national lab

\$55 Billion market

Clinical, Anatomic and Genomic Testing

Serving clients in all 50 states and Canada

Leading clinical trials testing business

2010 Priorities

4

Our Focus

Profitable revenue growth

IT and client connectivity

Continue scientific

leadership

Maintain price

Control costs

2010 Priorities

5

Profitable Revenue Growth

Target specialty physicians with

breadth of menu and services

Educate payers and physicians on

value of LabCorp testing

Leverage assets from Monogram

acquisition

Continue to improve patient experience

2010 Priorities

6

IT and Client Connectivity

Enhance online services and

analytic tools

LabCorp Inside the Box for

superior connectivity

Improve Patient Experience

through:

Automated PSC workflow

Patient access via PHRs,

online appointments

Enterprise services

including VoIP

Continue open platform strategy

to maximize options for users

Continue Scientific

Leadership

Increase esoteric testing

Grow and enhance offerings in

personalized medicine:

Expand outcome improvement

programs

Develop and commercialize

companion diagnostics

2010 Priorities

2010 Priorities

Maintain Price

Managed care stability; offsets

1.9% Medicare rate decrease

Focus on high-value tests

Promote outcome improvement

Control Costs

Continue focus on collections


and bad debt reduction

Optimize supply chain

Use efficiency gains to

improve patient experience

2010 Priorities



1.30
\$
1.22
\$
6.6%
Operating Cash Flow
232.0
\$
208.9
\$
11.1%
Less: Capital Expenditures
(24.5)
\$
(30.7)
\$
(20.2%)
Free Cash Flow
207.5
\$
178.2
\$
16.4%
(1) During the quarter inclement weather reduced revenue by an estimated \$23 million and EPS by approximately eight cents
Three Months Ended Mar 31,

Supplemental Financial Information 11 Q1 09 Q2 09 Q3 09 Q4 09 Q1 10 Bad debt as a percentage of sales 5.30% 5.30% 5.30% 5.30% 5.05% Days sales outstanding 52 **50** 48 44 46 A/R coverage (Allowance for Doubtful Accts. / A/R)

19.5%

	Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form 8-K
20.6%	
21.9%	
23.2%	
21.7%	
Laboratory Corp	poration of America
Other Financial	Information
FY 2009 and Q1	2010

(\$ in millions)

Superior Two-Year Return

LabCorp shares up 4.7%

S&P Healthcare Index down 11.3%

S&P 500 down 16.9%

S&P Financials Index down 42.1%

Stock Performance

12

Note: Period measured is from January 2^{nd} , 2008 May n , 2010

Source: First Call

Key Points

Critical position in health care delivery system

Attractive market

Strong competitive position - well positioned to gain share

Leadership in personalized medicine

Excellent cash flow

Strong balance sheet

Conclusion

14

©2010 LabCorp. All rights reserved. 6967-0409